PASADENA, CA, USA, March 4, 2020 /EINPresswire.com/ -- The American Society for Experimental Neurotherapeutics has invited Genervon Biopharmaceuticals to present its latest research data at the ASENT2020 Annual Meeting in Bethesda, MD from March 2-5. Genervon will address the unfortunate failures of many Alzheimer’s disease (AD) clinical trials and will propose a more plausible design for AD disease-modifying treatment trials which it has developed. Genervon will be giving a platform presentation on GM6’s effect in modulating Alzheimer’s disease
Genervon Presents Mechanisms of Actions in Alzheimer’s Disease, Including Results Confirming that GM6 Attenuates Alzheimer’s Disease in Mouse Model, in Part by Reducing Inflammation
PASADENA, Calif.--(BUSINESS WIRE)--Following the closure of several research programs for Alzheimer’s disease, in early 2018 the FDA issued a release entitled “Draft Guidance for Industry: Early Alzheimer’s Disease: Developing Drugs for Treatment.” Encouraged by the proposed changes in the new guidance, Genervon’s research team reported new findings that its drug candidate GM6 attenuates Alzheimer’s disease (AD) in an early AD transgenic APP mice model.
Genervon Presents Innovative CNS Drug Candidate at 2018 BIO CEO & Investor Conference
PASADENA, Calif. (Business Wire)—Winston Ko, founder and chairman of Genervon Biopharmaceuticals LLC (“Genervon”), presented the company’s history, research, and discoveries at the 2018 BIO CEO & Investor Conference at the New York Marriott Marquis on February 12, 2018. (Company Presentation and Interview attached.)
GM604 Is a Multi-Target Regulator That Provides a Novel Treatment Strategy for ALS
PASADENA, Calif.--(BUSINESS WIRE)--Genervon Biopharmaceuticals LLC ("Genervon") is presenting its recent findings at the 28th international symposium on ALS/MND in Boston on Saturday, December 9, 2017.
You are invited to our luncheon presentation - World Preclinical Congress, Translational Strategies In CNS
Mr. Winston Ko, Chairman and CEO, will present Genervon's disruptive and novel therapeutic strategy for diseases of the central nervous system and share pre-clinical and bioinformatic data as well as functional and bio-marker findings from clinical trials. Genervon has identified 1,259 genes altered greater than 2-fold in SH-5YSY cells by GM6 including 89, 48, 46 and 9 specific genes associated with ALS, AD, PD and MS respectively. GM6 discovered by Genervon is an endogenous multiple targets embryonic stage tyrosine kinase motoneuronotrophic factor neuronal regulator of the human nervous system.
Confidential data from Genervon ALS Phase 2A clinical trial were released and published
Genervon discovered the endogenous embryonic stage multi-target regulator GM6. GM6 modulates 89 ALS, 48 AD, 46 PD and 9 MS associated defective genes to bring homeostasis for the respective patient groups. Genervon embraced a system biology approach in finding a cure for the highly complex heterogeneous neurodegenerative and neurological diseases and disorders...